Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > I fail to understand
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(4)
•••
Post by Marky1on Feb 16, 2021 2:13pm
387 Views
Post# 32575292

I fail to understand

I fail to understand Why everyone here is under valuing ATE...We have Don who just completed a 4B$ USD deal

working for us. I am sure that he is drawing up a deal with Bayer as we speak! We have a brilliant
man who is world renowned and cited in references more than 95% of the worlds scientists... The minimum I see us at is 50$....the NSAIDS business has been waiting 50 years now for a product that we own...I agree with the Crow ( thank you )....other NSAIDS will be removed from the market when Bayer comes out with  super Alleve with no GI problems, at 1/4 the dose...faster acting, longer acting....in short BETTER than any other Medication
we have the science behind us,  we have the math behind us(P values ) we have the perfect people behind us'
anyways, stay long everyone...we have an absolute winner!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities